The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
To understand why cagrilintide represents a genuine mechanistic advance rather than just another weight loss drug, you first need to understand what amylin does and why it has been overlooked in the GLP-1 era.
Amylin, also called islet amyloid polypeptide (IAPP), is a 37-amino acid peptide hormone synthesized and secreted by pancreatic beta cells. Every time insulin is released in response to a meal, amylin is co-released in the same secretory vesicles at approximately a 1:100 molar ratio of amylin to insulin. Amylin is therefore an insulin co-secretagogue with a completely distinct receptor system and set of metabolic actions — not a variant of insulin, not a GLP-1, but a third pancreatic hormonal signal that operates in parallel with both.
Amylin's physiological actions constitute a meal-termination signal that is complementary to GLP-1 in every dimension: area postrema and nucleus tractus solitarius (brainstem): amylin acts on the area postrema (a circumventricular organ without a blood-brain barrier) and the adjacent NTS; these brainstem structures integrate satiety signals from multiple sources; amylin receptor activation here produces meal termination and nausea suppression of meal-continuing behavior. Gastric emptying: amylin slows gastric emptying rate, reducing the rate at which nutrients enter the small intestine; this blunts postprandial glucose excursions and prolongs the feeling of satiety. Glucagon suppression: amylin suppresses postprandial glucagon secretion — the same effect that GLP-1 produces, but through independent receptor systems. Hypothalamic energy balance: amylin receptors in the hypothalamus modulate long-term energy homeostasis signals beyond just acute meal termination.
Two facts make amylin particularly important: First, amylin is deficient or absent in people with obesity. Unlike in lean individuals where amylin rises appropriately after meals, people with obesity have blunted amylin responses — the satiety signal is weakened even though the pancreatic beta cells are intact. This is analogous to leptin resistance: the hormone can be present but its signaling is impaired. Replacing the amylin signal through pharmacological activation of amylin receptors can restore this component of meal termination that obesity has compromised. Second, amylin and GLP-1 activate completely different brain circuits. GLP-1 primarily activates hypothalamic neurons expressing the GLP-1 receptor; amylin primarily activates brainstem circuits through the AMY1R and AMY3R. The two pathways converge downstream but start from different receptors and different locations. This is why combining a GLP-1 agonist with an amylin agonist produces additive-to-synergistic effects: each compound is adding to a separate input stream.
THE CENTRAL TENSION
Cagrilintide is the most clinically advanced compound in this book — a Phase 3-completed, NEJM-published, Novo Nordisk-developed pharmaceutical that is weeks to months away from FDA approval as of mid-2026. The Phase 3 REDEFINE 1 trial combining cagrilintide with semaglutide produced 22.7% average body weight loss at 68 weeks — one of the highest weight loss figures ever reported in a randomized clinical trial of obesity medication. Cagrilintide monotherapy produces 11.8% weight loss through an entirely different mechanism than GLP-1. The compound represents the first genuinely new mechanism to emerge in obesity pharmacology since GLP-1: amylin receptor activation from a complementary brainstem circuit. Community members are self-administering it as a research chemical in advance of its FDA approval — running ahead of the pharmaceutical timeline by months rather than years. The safety profile appears favorable; the primary concern (calcitonin receptor → MTC risk) is a class effect shared with GLP-1 agents. The benefit-risk ratio for community use in the window before FDA approval is different from other research chemicals in this book — this compound has completed Phase 3 and the FDA is reviewing it.
The REDEFINE trials documented cagrilintide's general safety profile: the adverse event pattern for cagrilintide monotherapy is similar to but milder than GLP-1 agonists. Most common adverse events: nausea (primary; mild-to-moderate; concentrated during dose escalation; typically resolves within 4-8 weeks); vomiting; diarrhea; constipation. Onset during dose escalation: cagrilintide, like semaglutide, uses a gradual dose escalation protocol to improve tolerability — starting at lower doses and increasing over weeks to the 2.4mg target dose. The GI side effect burden appears lower than high-dose semaglutide, which is one of cagrilintide's potential advantages as a monotherapy or in the combination. Discontinuation rate: only 1.0% of cagrilintide participants in REDEFINE 1 discontinued — exceptionally low for an active treatment arm in an obesity trial.
THE CALCITONIN RECEPTOR AND MEDULLARY THYROID CARCINOMA — CLASS EFFECT EXPLANATION
Cagrilintide activates calcitonin receptors (CTR) as part of its amylin receptor mechanism (AMY1R and AMY3R both incorporate CTR). CTR agonism in rodent studies causes thyroid C-cell hyperplasia and medullary thyroid carcinoma (MTC). This is the same concern associated with GLP-1 receptor agonists (which carry black box FDA warnings for MTC), though the mechanisms differ. For cagrilintide: the MTC concern is a class effect of calcitonin receptor agonism in rodents; human epidemiological data from GLP-1 agents (which have been used in millions of patients for years) has not shown a clinical increase in MTC incidence; however, the lack of human signal does not eliminate the theoretical risk. PRACTICAL CONTRAINDICATIONS (expected to apply to cagrilintide's eventual label, by analogy with GLP-1 agents): personal or family history of medullary thyroid carcinoma (MTC); multiple endocrine neoplasia syndrome type 2 (MEN2); any thyroid cancer history or concerns should prompt endocrinologist consultation before use. Community users should apply the same MTC-related precautions they would for semaglutide.
Cagrilintide's behavioral profile is relevant to the C4 audit: Appetite and food reward: amylin receptor activation reduces food reward through brainstem circuits — some evidence that amylin signaling reduces the motivational salience of high-palatability foods (the 'wanting' component of food reward). This is mechanistically complementary to GLP-1 but different in character — amylin appears more specifically targeted at high-fat food motivation, particularly in the context of insulin and postprandial signals. Mood and energy: unlike tesofensine (which elevates monoamines and produces stimulant-like energy), cagrilintide's amylin mechanism does not directly affect monoaminergic neurotransmitter systems. Mood changes in clinical trials are generally positive (correlated with weight loss and improved metabolic health) rather than pharmacologically driven. Nausea: the most behaviorally relevant side effect — can be uncomfortable and distressing, particularly in dose escalation; resolves for most participants. No evidence for psychological dependence, reward pathway activation, or withdrawal syndrome.
Cagrilintide is a synthetic analogue of human amylin with two key engineering modifications: amino acid substitutions throughout the sequence that eliminate the natural tendency of amylin to form toxic amyloid fibrils (native amylin self-aggregates into beta-sheet fibrils in physiological conditions, contributing to beta cell toxicity — the engineered analogues avoid this); and C18 fatty acid lipidation linked via a linker to a lysine residue in the peptide chain. The lipidation is the same engineering strategy used in semaglutide (C18 fatty acid) and liraglutide — it allows non-covalent binding to albumin in circulation, dramatically extending the half-life from amylin's natural few minutes to approximately one week. This pharmacokinetic engineering enables once-weekly dosing, which is the practical foundation of cagrilintide's clinical utility.
Amylin receptors are heterodimeric complexes composed of the calcitonin receptor (CTR) plus one of three receptor activity modifying proteins (RAMP1, RAMP2, or RAMP3). The three resulting receptor subtypes — AMY1R (CTR + RAMP1), AMY2R (CTR + RAMP2), and AMY3R (CTR + RAMP3) — have overlapping but distinct expression patterns and pharmacological properties. Cagrilintide activates AMY1R and AMY3R as the primary mechanism for its anorectic effects — established by the 2025 PMC study using RAMP1/3 knockout mice. Calcitonin receptor (CTR) activation: because AMY1R and AMY3R both incorporate CTR, cagrilintide necessarily also activates CTR to some degree. The relative balance between pure CTR activation and AMY1R/AMY3R activation is determined by the RAMP component. The CTR activity is responsible for the calcitonin-receptor class safety concern (C-cell hyperplasia / MTC risk).
The anatomical distribution of amylin receptors relevant to energy balance: area postrema (AP): high density of AMY1R and AMY3R; this circumventricular organ lacks a blood-brain barrier, allowing direct peptide access from the bloodstream; cagrilintide activates AP neurons within 30-60 minutes of injection. Nucleus tractus solitarius (NTS): immediately adjacent to the AP; processes satiety signals from the vagus nerve, GI tract, and amylin; NTS activation is critical for meal termination. Hypothalamus — arcuate nucleus and lateral hypothalamus: amylin receptors are present but less dense than brainstem; hypothalamic amylin signaling contributes to longer-term energy homeostasis. GLP-1 receptor distribution: GLP-1 receptors are highly expressed in the hypothalamic arcuate nucleus (ARC), ventromedial hypothalamus, NTS, and vagal afferents. The brainstem (AP/NTS) circuits activated by amylin and GLP-1 have some overlap (both signal through NTS) but different receptor systems and different relative emphasis. The hypothalamic GLP-1 receptor activation by semaglutide provides long-term energy balance modulation; the brainstem amylin receptor activation by cagrilintide provides meal-by-meal satiety signals. The two mechanisms thus address both the acute meal termination dimension (amylin, brainstem) and the long-term energy set point dimension (GLP-1, hypothalamus) of obesity.
REDEFINE 1 and REDEFINE 2 represent the most significant new obesity pharmacotherapy clinical trial data published in 2025. Both were published simultaneously in the New England Journal of Medicine on June 22, 2025, concurrent with presentation at ADA Scientific Sessions.
Garvey WT, Blüher M, Osorto Contreras CK, et al. (NEJM, June 22, 2025, doi:10.1056/NEJMoa2502081). Design: randomized, double-blind, placebo-controlled, 4-arm, 68-week Phase 3 trial. Population: n=3,417 adults with BMI ≥27 and ≥1 weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, sleep apnea, etc.); no diabetes. Arms: CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg, once weekly); cagrilintide 2.4mg alone; semaglutide 2.4mg alone; placebo. All with lifestyle intervention. PRIMARY ENDPOINT — Weight loss at 68 weeks: CagriSema intent-to-treat = -20.4%; CagriSema on-treatment (if all adhered) = -22.7%; semaglutide alone = -14.9%; cagrilintide alone = -11.5%; placebo = -3.0%. Responder analysis: 40.4% of CagriSema participants achieved ≥25% weight loss; 22% achieved ≥30%; 31.6% of cagrilintide monotherapy participants achieved ≥15% weight loss. SECONDARY ENDPOINTS: waist circumference reduction; improvements in blood pressure, lipids, C-reactive protein; cardiovascular risk factor improvements.
The synergy significance: the CagriSema -22.7% result is meaningfully greater than either component alone (semaglutide -14.9%; cagrilintide -11.5%). A purely additive model would predict approximately: -14.9% + (-11.5% - (-3.0% placebo)) = approximately -23.4% — remarkably close to the observed -22.7%, suggesting near-additive rather than synergistic in the strict pharmacological sense. Regardless of classification, the combination achieves weight loss that exceeds both components alone and exceeds tirzepatide's Phase 3 results (~22.5% in SURMOUNT-1), positioning CagriSema among the most effective obesity medications ever tested. The -22.7% figure is on-treatment (assuming full adherence); the intent-to-treat figure is -20.4%.
Davies MJ, Bajaj HS, Broholm C, et al. (NEJM, June 22, 2025, doi:10.1056/NEJMoa2502082). Population: n=~1,200 adults with BMI ≥27, HbA1c 7-10%, established T2D. Arms: CagriSema vs placebo (two-arm design). PRIMARY RESULTS: CagriSema = -15.7% body weight (intent-to-treat) / approximately -16% on-treatment; placebo = -3.4%. Glycemic control: 74% of CagriSema participants achieved HbA1c ≤6.5% vs 15.9% with placebo — this normalization of blood sugar in 74% of T2D patients is a remarkable result. Low hypoglycemia incidence despite dramatic glucose lowering. The T2D population shows less weight loss than non-diabetic patients (typical for all weight loss medications) but significantly better glycemic outcomes from the combined amylin + GLP-1 signaling.
Presented at EASD (European Association for the Study of Diabetes) September 16, 2025, Vienna. This sub-analysis specifically examined cagrilintide monotherapy from REDEFINE 1's cagrilintide-alone arm. Findings: 11.8% mean body weight reduction vs 2.3% placebo at 68 weeks; 31.6% of cagrilintide participants achieved ≥15% weight loss; only 1.0% of cagrilintide participants discontinued the trial. Safety: mild-to-moderate GI adverse events (nausea primarily) during dose escalation; generally well-tolerated. These results led Novo Nordisk to initiate the dedicated RENEW Phase 3 program for cagrilintide monotherapy in Q4 2025 — establishing a path for cagrilintide to receive separate approval as a monotherapy, not only as part of CagriSema.
Indication
Grade
Key Evidence
Magnitude
CagriSema — obesity without T2D
A
Garvey et al. NEJM June 22, 2025; n=3,417; 68 weeks; REDEFINE 1
22.7% (on-treatment); 20.4% (intent-to-treat); 40.4% ≥25% weight loss
CagriSema — obesity with T2D
A
Davies et al. NEJM June 22, 2025; n=~1,200; 68 weeks; REDEFINE 2
~15.7-16% weight loss; 74% achieved HbA1c ≤6.5%
Cagrilintide monotherapy
B
REDEFINE 1 sub-analysis; EASD Sept 2025; n=3,417 (cagrilintide arm)
11.8% vs 2.3% placebo; 31.6% achieved ≥15%
Semaglutide component (reference)
A
REDEFINE 1 semaglutide arm (2.4mg)
14.9% — consistent with STEP 1 (16.9%) historical data
Comparative efficacy
A
4-arm head-to-head in REDEFINE 1
CagriSema > sema alone > cagri alone > placebo; confirmed synergy
Pramlintide was the first amylin analogue and proof that amylin receptor agonism produces clinically meaningful weight loss. Why did it not become widely used? And why does cagrilintide change the picture?
Pramlintide (Symlin): FDA-approved 2005 for T1D and T2D. Subcutaneous injection required immediately before every meal — three or more injections per day — without which the pharmacological window is missed. Injection at separate sites from insulin required. Complex regimen, high pill/injection burden, frequent dosing errors. Despite genuine efficacy (3-4 kg weight loss, improved postprandial glucose control), pramlintide achieved minimal market penetration because of the demanding administration schedule. The practical barrier was the fundamental obstacle: amylin's natural half-life is only a few minutes, and pramlintide, though more stable than native amylin, still required meal-time dosing. Cagrilintide solved this problem entirely through lipidation engineering — the same approach Novo Nordisk used to create semaglutide from liraglutide. One weekly injection replacing three-or-more daily injections. The clinical result: 11.8% weight loss as monotherapy vs pramlintide's historical 3-4 kg — an order of magnitude difference, primarily because sustained 24/7 receptor engagement is possible with the weekly formulation rather than only the brief post-meal window pramlintide covers.
Cagrilintide occupies a unique regulatory position among all compounds in this book: it is not a research chemical with indefinite unknowns, but a pharmaceutical days-to-months from FDA approval whose community use is running slightly ahead of the approval timeline.
CagriSema NDA filing: Novo Nordisk announced FDA NDA filing for CagriSema in Q1 2026. FDA standard review timeline is 10-12 months from NDA acceptance; priority review (possible given obesity burden) could be 6 months. Anticipated FDA approval: late 2026 to early 2027 for CagriSema. Cagrilintide monotherapy: RENEW Phase 3 started Q4 2025; approval timeline for cagrilintide alone is 2-3 years pending RENEW completion. The practical implication: community users accessing research chemical cagrilintide are using a compound approximately 6-18 months ahead of formal US regulatory approval — not a compound decades from approval or in early Phase 2.
The most significant risk in community access to cagrilintide is quality and authenticity. As a long-acting lipidated peptide manufactured by Novo Nordisk for clinical use, pharmaceutical-grade cagrilintide requires sophisticated manufacturing infrastructure (solid-phase peptide synthesis + lipidation conjugation + purification + lyophilization under pharmaceutical GMP conditions). Research chemical vendors supplying 'cagrilintide' cannot be independently verified for: purity (peptide synthesis impurities, lipidation byproducts); structural accuracy (correct amino acid sequence and modifications); endotoxin contamination (injectable material must be sterile and pyrogen-free); actual cagrilintide content vs labeled content. The complexity of lipidated peptide synthesis means quality variation is a meaningful concern. This is distinct from simpler peptides like BPC-157 or thymosin, where synthesis is straightforward. Users should prioritize vendors with published mass spectrometry certificates of analysis.
The clinical trial dose: 2.4mg once weekly subcutaneous injection, using a dose escalation protocol (typically starting at 0.25-0.3mg and increasing over 12-16 weeks to the 2.4mg target dose). The dose escalation is essential for tolerability — the nausea pattern in clinical trials concentrated at dose escalation, after which most participants were comfortable. Community protocols: generally follow the clinical trial escalation schedule; start at 0.25mg weekly; increase by 0.25mg weekly or fortnightly; target 2.4mg/week. The 2.4mg dose is the Phase 3 validated dose; lower doses produce proportionally less weight loss. Reconstitution: lyophilized powder with bacteriostatic water; typical commercial formulation 5mg/vial; storage at 2-8°C.
The obesity pharmacotherapy landscape has been transformed by GLP-1 agonists. Cagrilintide and CagriSema represent the next wave — but understanding where they fit requires understanding what each compound adds.
Compound
Mechanism
Phase 3 Weight Loss
Approved
Notes
Semaglutide 2.4mg (Wegovy)
GLP-1 agonist
~16.9% (STEP 1)
FDA approved 2021
Established first-line; once weekly; cardiovascular outcome data available
Tirzepatide (Zepbound)
GLP-1 + GIP dual agonist
~22.5% (SURMOUNT-1)
FDA approved 2023
Currently highest approved efficacy; once weekly
CagriSema
GLP-1 + amylin dual agonist
22.7% (REDEFINE 1)
NDA filed Q1 2026; not yet approved
Comparable to tirzepatide; NEJM June 2025; combination product
Cagrilintide monotherapy
Amylin receptor agonist
11.8% (REDEFINE 1 sub-analysis)
NDA not yet filed (RENEW ongoing)
First amylin-only once-weekly; distinct mechanism from all others
Pramlintide
Amylin analogue (short-acting)
~3-4 kg (historical)
FDA approved 2005; limited use
TID meal-time injection; superseded by cagrilintide pharmacokinetics
Tesofensine
Triple monoamine reuptake inhibitor
~11% (Lancet Phase 2b)
Mexico only (Tesomet); not FDA approved
Different mechanism; heart rate concern; Phase 3 incomplete
The combination of GLP-1 + amylin outperforms either alone not because amylin is more potent than GLP-1, but because they address different dimensions of obesity's pathophysiology. GLP-1's hypothalamic effect primarily addresses long-term energy set point — it reduces the body's defended weight over months. Amylin's brainstem effect primarily addresses meal-by-meal satiety — it reduces the size of each individual meal through area postrema and NTS signaling. The mechanisms converge at the NTS but diverge at the receptor level and in their temporal profiles. Additionally, amylin specifically suppresses glucagon (independent of GLP-1's glucagon suppression mechanism — two separate inputs to the same function) and slows gastric emptying through a distinct mechanism. The clinical result is that even in patients already maximally suppressing appetite via GLP-1, the additional amylin pathway adds an independent incremental weight loss contribution.
Cagrilintide is not a GLP-1 receptor agonist. It does not bind or activate the GLP-1 receptor. It activates amylin receptors (AMY1R, AMY3R) — heterodimeric complexes of calcitonin receptor + RAMP proteins. The mechanism, receptor system, brain distribution, and clinical profile all differ from GLP-1 agonists. The clinical evidence confirms this: in REDEFINE 1, cagrilintide and semaglutide produced independently significant weight loss in their separate arms, and the combination exceeded either alone.
CagriSema is semaglutide + cagrilintide — two distinct compounds with distinct mechanisms. The 22.7% weight loss in CagriSema exceeds semaglutide alone (14.9%) by approximately 7-8 percentage points. This is a clinically and statistically significant addition, not a marginal increment. Cagrilintide's contribution is independent — it would work even in patients who have already maximized GLP-1 receptor agonism through semaglutide.
22.7% is the mean on-treatment result — if all participants had adhered to treatment. The intent-to-treat figure (including discontinuations and non-completers) is 20.4%. Individual results vary considerably: some participants achieved ≥30% weight loss; some achieved less than 5%. The distribution of responses is wide. 22.7% is the central tendency, not a guarantee. A clinically important minority — about 40% — achieved ≥25% weight loss; 22% achieved ≥30%. The response distribution is meaningful for setting patient expectations.
Cagrilintide's GI side effect profile (nausea, vomiting, diarrhea) is qualitatively similar to GLP-1 agonists — both classes work through overlapping brainstem satiety pathways that produce nausea as a consequence of potent anorectic signaling. In REDEFINE 1, the GI adverse event rate for CagriSema was 79.6% (consistent with combined amylin + GLP-1 signaling), with the majority of events mild-to-moderate and transient. Cagrilintide monotherapy's GI burden appears somewhat lower than high-dose semaglutide, but nausea during dose escalation is expected. The claim of 'no GI side effects' relative to GLP-1 is incorrect.
Garvey WT, Blüher M, Osorto Contreras CK, et al. (2025). Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine. doi:10.1056/NEJMoa2502081. Published June 22, 2025. [REDEFINE 1: n=3,417; 68 weeks; CagriSema 22.7% vs placebo 3.0% weight loss; 4-arm head-to-head; the landmark Phase 3 paper.]
Davies MJ, Bajaj HS, Broholm C, et al. (2025). Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. New England Journal of Medicine. doi:10.1056/NEJMoa2502082. Published June 22, 2025. [REDEFINE 2: n=~1,200 T2D; CagriSema ~15.7% weight loss; 74% achieved HbA1c ≤6.5% vs 15.9% placebo.]
Garvey WT, Kuhlman AB, Rømer J, et al. (2025). Efficacy and safety of cagrilintide 2.4 mg in adults with overweight/obesity: data from REDEFINE 1. Late-breaking presentation at EASD 2025 annual meeting, Vienna, September 15-19, 2025. [First Phase 3 data for cagrilintide monotherapy; 11.8% vs 2.3% placebo; 31.6% ≥15% weight loss; 1.0% discontinuation; basis for RENEW program initiation.]
Oliveira Carvas A, Leuthardt A, Kulka P, et al. (2025). Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eBioMedicine / PMC12270663. Published July 3, 2025. [RAMP1/3 knockout mouse study; AMY1R and AMY3R are the primary receptors mediating cagrilintide's anorectic effects; distinguishes from pure CTR activation; foundational mechanistic paper.]
Novo Nordisk press release. September 16, 2025. Cagrilintide Phase 3 data presented at EASD; RENEW program Q4 2025 initiation announced. [Corporate announcement of RENEW program based on REDEFINE 1 sub-analysis results.]
Cagrilintide is the most clinically advanced and evidence-supported novel compound in this book — an amylin analogue backed by Phase 3 NEJM publications, weeks-to-months from FDA approval as part of CagriSema.
The central tension resolved: cagrilintide represents the first genuinely new mechanism in obesity pharmacology since GLP-1 — amylin receptor activation through AMY1R and AMY3R in the brainstem, complementary to but non-overlapping with GLP-1's hypothalamic mechanism. In combination with semaglutide (CagriSema), the Phase 3 REDEFINE 1 trial produced 22.7% mean body weight loss at 68 weeks — published in the New England Journal of Medicine in June 2025, establishing one of the highest weight loss figures ever reported in an obesity pharmacotherapy trial. The evidence is among the strongest in this entire book. The regulatory trajectory is clear: CagriSema NDA was filed Q1 2026; approval expected late 2026 to early 2027. Community users accessing research chemical cagrilintide are working with a compound that is months rather than years from mainstream availability — a fundamentally different situation than most research chemicals in this book.
The practical guidance: for community members currently using cagrilintide as a research chemical, the dose escalation protocol from the clinical trials is the evidence-based approach (0.25mg weekly, escalating to 2.4mg over 12-16 weeks). The MTC calcitonin receptor concern is a class effect shared with GLP-1 agents — apply the same personal/family MTC history exclusion as for semaglutide. The nausea during dose escalation is expected and manageable. The quality of research chemical cagrilintide is the most significant practical uncertainty. For the community member who has access to pharmaceutical-grade product (e.g., through a physician compounding protocol in advance of approval), the benefit-risk ratio of cagrilintide — especially as part of a CagriSema-equivalent protocol — is excellent.
— End of Cagrilintide —
THE PEPTIDE BIBLE | Cagrilintide | For Research & Educational Purposes Only
Cagrilintide: long-acting lipidated synthetic amylin analogue. Dual amylin/calcitonin receptor agonist. Once-weekly subcutaneous injection 2.4mg. Developed by Novo Nordisk. AMYLIN BIOLOGY: amylin (IAPP) co-secreted with insulin by pancreatic β-cells; deficient in obesity (blunted meal response); activates area postrema and NTS in brainstem for meal termination; slows gastric emptying; suppresses postprandial glucagon; completely different receptor system from GLP-1. MECHANISM: activates AMY1R (CTR+RAMP1) and AMY3R (CTR+RAMP3) in brainstem (area postrema, NTS) and hypothalamus; lipidation enables once-weekly dosing (t1/2 ~1 week via albumin binding vs native amylin t1/2 minutes). RECEPTOR STRUCTURE: amylin receptors = heterodimers of calcitonin receptor (CTR) + RAMP1-3; CTR activity responsible for calcitonin class safety concern (MTC). REDEFINE 1 (NEJM, June 22, 2025, Garvey et al., doi:10.1056/NEJMoa2502081): n=3,417 adults; no T2D; 68 weeks; 4-arm DBRCT: CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) = 22.7% (on-treatment) / 20.4% (ITT); semaglutide alone = 14.9%; cagrilintide alone = 11.5%; placebo = 3.0%; 40.4% CagriSema ≥25% weight loss; 22% ≥30%. Grade A. REDEFINE 2 (NEJM, June 22, 2025, Davies et al., doi:10.1056/NEJMoa2502082): n=~1,200 T2D; CagriSema ~15.7-16% weight loss; 74% achieved HbA1c ≤6.5% vs 15.9% placebo. Grade A. CAGRILINTIDE MONOTHERAPY: 11.8% vs 2.3% placebo; REDEFINE 1 sub-analysis; EASD September 2025; 31.6% achieved ≥15%; 1.0% discontinuation. Grade B. RENEW Phase 3 monotherapy program: started Q4 2025. SYNERGY: cagrilintide (brainstem AMY1R/AMY3R) + semaglutide (hypothalamic GLP-1R) = distinct circuits + mechanisms = additive/synergistic effect; 22.7% > either alone. PRAMLINTIDE COMPARISON: pramlintide required TID injection; cagrilintide's weekly lipidation solves the practical obstacle; 11.8% monotherapy vs ~3-4 kg historical for pramlintide. SAFETY: GI side effects (nausea, vomiting) during dose escalation — primarily mild-to-moderate, transient; 79.6% any GI AE in CagriSema; 1.0% discontinuation cagrilintide alone; MTC CALCITONIN RECEPTOR CLASS CONCERN: apply same MTC history exclusion as for GLP-1 agonists. REGULATORY: CagriSema NDA filed Q1 2026; approval expected late 2026/early 2027. Cagrilintide monotherapy: RENEW Phase 3 ongoing; separate NDA not yet filed. COMMUNITY: research chemical available but complex lipidated peptide synthesis requires mass spec CoA verification. DOSE ESCALATION: 0.25mg/week start, escalate to 2.4mg/week over 12-16 weeks. WADA: not currently listed.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.